Soft Contact Lenses Do Not Lead to 'Myopic Creep' in Children, S...(s wearersprogressed -1.27 +/- 0.72 D (an...),Health

Date:11/12/2008

s wearers progressed -1.27 +/- 0.72 D (analysis of covariance, p = 0.005); although this difference is statistically significant, the difference is less than can be clinically measured. The axial growth of the spectacle wearers was 0.59 +/- 0.37 mm and 0.63 +/- 0.34 mm for the contact lens wearers (analysis of covariance, p = 0.27). The change in the steep corneal meridian was 0.05 +/- 0.69 D for the spectacle wearers and 0.10 +/- 0.70 D for the contact lens wearers (analysis of covariance, p = 0.43). These differences were not statistically significant.

The study was supported by funding from VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc.

ACUVUE(R), Brand Contact Lenses are indicated for vision correction. As with any contact lenses, eye problems, including corneal ulcers, can develop. Some wearers may experience mild irritation, itching or discomfort. Lenses should not be prescribed if patients have any eye discomfort, excessive tearing, vision changes, redness or other eye problems. Consult the package insert for complete information. Complete information is also available from VISTAKON(R), Division of Johnson & Johnson Vision Care, Inc., by calling 1-800-843-2020 or by visiting http://www.jnjvisioncare.com (for eye care professionals) or http://www.acuvue.com (for consumers).

ACUVUE(R), ACUVUE(R) 2, 1-DAY ACUVUE(R) and VISTAKON(R) are trademarks of Johnson & Johnson Vision Care, Inc.

'/>"/>

SOURCE VISTAKON, Division of Johnson & Johnson Vision Care, Inc. Copyright©2008 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3
Related medicine technology :

1. Pediatric Study Finds 21st Century Non-Contact Thermometer as Accurate as Conventional Thermometers
2. New Implantable Lenses Can Reduce the Need for Glasses After Cataract Surgery
3. Study Says Allergy Shots Help Children, Reduce Health Care Costs
4. New Risk Factor for Heart Disease Identified in Very Young Children, According to Study at American Heart Association Scientific Sessions
5. Miami Jewish Home and Hospital, Berma Research Group and Segal Institute for Clinical Research Enrolling Local Patients in Study of Investigational Therapy to Treat Alzheimers Disease
6. Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease
7. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
8. Physicians Health Study II Finds No Magic Bullet for Preventing Cardiovascular Disease
9. Study Showed Prevention of Heart Attacks Within Three Months After Hospitalization Significantly Averted Future Heart Attacks and Death
10. CRESTOR Demonstrates Dramatic CV Risk Reduction in a Large Statin Outcomes Study
11. Study Shows Potential Benefits of Xolair(R) in Treating Children Suffering from Moderate or Severe Persistent Allergic Asthma Inadequately Controlled With Inhaled Corticosteroids